This result signifies that the patient has a copy of the MT-RNR1 [variant]. Based on this genotype result, the patient is predicted to be at increased risk of aminoglycoside-induced hearing loss. This means that the patient is likely to develop irreversible hearing loss if aminoglycosides (e.g. amikacin, gentamicin, tobramycin) are prescribed. Please consult a clinical pharmacist or Infectious Diseases Service for help selecting alternative therapies.